AGEN

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Agenus Inc

NASDAQ | AGEN

3.88

USD

$0.00

(

0.00%

)

At Close (As of Oct 17, 2025)

$123.63M

Market Cap

-

P/E Ratio

-7.06

EPS

$7.34

52 Week High

$1.38

52 Week Low

HEALTHCARE

Sector

AGEN Chart

Recent Chart
Price Action

AGEN Technicals

Tags:

AGEN Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$53M
Total Revenue $103M
Cost Of Revenue $156M
Costof Goods And Services Sold $156M
Operating Income -$120M
Selling General And Administrative $72M
Research And Development $156M
Operating Expenses $68M
Investment Income Net -
Net Interest Income -$118M
Interest Income -
Interest Expense $118M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $13M
Income Before Tax -$232M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$232M
Comprehensive Income Net Of Tax -
Ebit -$115M
Ebitda -$101M
Net Income -$227M

Revenue & Profitability

Earnings Performance

AGEN Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $226M
Total Current Assets $46M
Cash And Cash Equivalents At Carrying Value $40M
Cash And Short Term Investments $40M
Inventory -
Current Net Receivables $407K
Total Non Current Assets $181M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $3.4M
Intangible Assets Excluding Goodwill $3.4M
Goodwill $24M
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $4.7M
Other Non Current Assets -
Total Liabilities $533M
Total Current Liabilities $221M
Current Accounts Payable $61M
Deferred Revenue -
Current Debt -
Short Term Debt $9.8M
Total Non Current Liabilities $311M
Capital Lease Obligations $62M
Long Term Debt $30M
Current Long Term Debt $2.7M
Long Term Debt Noncurrent -
Short Long Term Debt Total $95M
Other Current Liabilities $150M
Other Non Current Liabilities $225M
Total Shareholder Equity -$326M
Treasury Stock -
Retained Earnings -$2.2B
Common Stock $236K
Common Stock Shares Outstanding $21M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$158M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $13M
Capital Expenditures $576K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $27K
Cashflow From Financing $123M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity $0
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$232M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$53M
Total Revenue $103M
Cost Of Revenue $156M
Costof Goods And Services Sold $156M
Operating Income -$120M
Selling General And Administrative $72M
Research And Development $156M
Operating Expenses $68M
Investment Income Net -
Net Interest Income -$118M
Interest Income -
Interest Expense $118M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $13M
Income Before Tax -$232M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$232M
Comprehensive Income Net Of Tax -
Ebit -$115M
Ebitda -$101M
Net Income -$227M

AGEN News

AGEN Profile

Agenus Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Agenus Inc. is a leading clinical-stage immuno-oncology company focused on discovering and developing innovative immunotherapy treatments aimed at enhancing the body’s immune response against cancer. Headquartered in Lexington, Massachusetts, Agenus is at the forefront of research in checkpoint inhibitors and other immunotherapies, positioning itself as a key player in the rapidly evolving oncology landscape. With a robust pipeline of therapeutics and a commitment to advancing patient care, Agenus is poised to capitalize on the increasing demand for effective cancer treatments globally.

VHAI
-25.00%
$0.00
RANI
+248.26%
$1.64
BYND
+24.15%
$0.64
YYAI
+0.83%
$0.12
YDKG
-40.50%
$0.05
CGBS
-39.47%
$0.03
BITF
-5.11%
$5.01
NVDA
+0.77%
$183.22
INTC
+0.46%
$37.01
RGTI
-3.31%
$46.38
GDXD
+20.23%
$0.72
F
+1.53%
$11.92
PLUG
-2.29%
$3.40
ARTV
+116.96%
$6.01
BURU
+0.85%
$0.34
TSLA
+2.46%
$439.31
DNN
-5.50%
$2.92
BBD
+1.22%
$3.30
IONZ
+7.55%
$3.70
HBAN
+0.84%
$15.50
NIO
-1.17%
$6.75
CAN
-4.19%
$1.60
NVTS
-6.20%
$14.66
HIMS
-15.84%
$49.78
RXRX
-7.86%
$5.86
TLRY
+1.29%
$1.56
AXDX
-61.36%
$0.03
BTG
-6.56%
$5.55
HPE
+2.04%
$22.96
LAES
+4.87%
$6.67
RGTZ
+6.58%
$11.97
T
+0.53%
$26.34
ETHD
+2.25%
$4.09
ELBM
+35.36%
$2.22
BLMZ
-3.85%
$0.18
ACHR
-5.30%
$11.24
AMD
-0.63%
$233.08
WTO
-47.99%
$0.07
CIFR
+0.21%
$18.76
KVUE
+8.36%
$15.29
GNPX
-23.68%
$0.36
LNKS
+30.35%
$0.73
RIG
+0.92%
$3.26
GPUS
-11.96%
$0.32
MARA
-3.42%
$19.57
AAPL
+1.95%
$252.29
BAC
+1.66%
$51.28
SOFI
-0.22%
$26.54
JOBY
-2.55%
$15.66
SOUN
-8.38%
$19.02
RF
+0.98%
$23.58
AMZN
-0.66%
$213.04
QBTS
-5.26%
$38.33
PLTR
+0.01%
$178.15
EPWK
-18.45%
$0.07
ONDS
-7.19%
$7.61
GRAB
-1.22%
$5.64
QUBT
-2.18%
$18.32
ADAP
+2.51%
$0.20
PFE
+1.15%
$24.51
RMBL
+60.50%
$3.21
SLB
-0.88%
$32.63
BMNR
-2.40%
$49.85
ABEV
+0.89%
$2.25
IREN
-1.79%
$60.72
ASST
-7.28%
$0.83
ADD
-25.47%
$0.05
SNAP
-1.41%
$7.65
ORCL
-6.92%
$291.31
CRML
+7.41%
$20.86
DFLI
+2.25%
$1.36
BTBT
-1.08%
$3.65
VIVK
-29.17%
$0.20
SRM
+53.27%
$10.30
AAL
-0.25%
$11.86
NEHC
+44.44%
$4.55
NUAI
+44.44%
$4.55
IONQ
-4.04%
$62.94
WULF
+0.50%
$13.93
NAK
-8.48%
$2.04
NOK
+1.05%
$5.74
ATAI
+17.70%
$6.45
RR
-4.05%
$5.44
SMR
-7.11%
$44.25
CLSK
-2.32%
$19.52
GWH
+16.04%
$5.28
APLD
-6.55%
$34.24
CRWV
-3.43%
$136.87
YGMZ
-6.12%
$0.92
UUUU
-2.90%
$21.06
QS
-0.64%
$15.36
GOOGL
+0.73%
$253.30
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
VALE
-0.09%
$11.10
WLGS
-5.57%
$0.04
FNB
+3.00%
$15.09
BULL
-6.29%
$11.01
AG
-8.48%
$14.03
FEMY
-5.67%
$0.70
VHAI
-25.00%
$0.00
RANI
+248.26%
$1.64
BYND
+24.15%
$0.64
YYAI
+0.83%
$0.12
YDKG
-40.50%
$0.05
CGBS
-39.47%
$0.03
BITF
-5.11%
$5.01
NVDA
+0.77%
$183.22
INTC
+0.46%
$37.01
RGTI
-3.31%
$46.38
GDXD
+20.23%
$0.72
F
+1.53%
$11.92
PLUG
-2.29%
$3.40
ARTV
+116.96%
$6.01
BURU
+0.85%
$0.34
TSLA
+2.46%
$439.31
DNN
-5.50%
$2.92
BBD
+1.22%
$3.30
IONZ
+7.55%
$3.70
HBAN
+0.84%
$15.50
NIO
-1.17%
$6.75
CAN
-4.19%
$1.60
NVTS
-6.20%
$14.66
HIMS
-15.84%
$49.78
RXRX
-7.86%
$5.86
TLRY
+1.29%
$1.56
AXDX
-61.36%
$0.03
BTG
-6.56%
$5.55
HPE
+2.04%
$22.96
LAES
+4.87%
$6.67
RGTZ
+6.58%
$11.97
T
+0.53%
$26.34
ETHD
+2.25%
$4.09
ELBM
+35.36%
$2.22
BLMZ
-3.85%
$0.18
ACHR
-5.30%
$11.24
AMD
-0.63%
$233.08
WTO
-47.99%
$0.07
CIFR
+0.21%
$18.76
KVUE
+8.36%
$15.29
GNPX
-23.68%
$0.36
LNKS
+30.35%
$0.73
RIG
+0.92%
$3.26
GPUS
-11.96%
$0.32
MARA
-3.42%
$19.57
AAPL
+1.95%
$252.29
BAC
+1.66%
$51.28
SOFI
-0.22%
$26.54
JOBY
-2.55%
$15.66
SOUN
-8.38%
$19.02
RF
+0.98%
$23.58
AMZN
-0.66%
$213.04
QBTS
-5.26%
$38.33
PLTR
+0.01%
$178.15
EPWK
-18.45%
$0.07
ONDS
-7.19%
$7.61
GRAB
-1.22%
$5.64
QUBT
-2.18%
$18.32
ADAP
+2.51%
$0.20
PFE
+1.15%
$24.51
RMBL
+60.50%
$3.21
SLB
-0.88%
$32.63
BMNR
-2.40%
$49.85
ABEV
+0.89%
$2.25
IREN
-1.79%
$60.72
ASST
-7.28%
$0.83
ADD
-25.47%
$0.05
SNAP
-1.41%
$7.65
ORCL
-6.92%
$291.31
CRML
+7.41%
$20.86
DFLI
+2.25%
$1.36
BTBT
-1.08%
$3.65
VIVK
-29.17%
$0.20
SRM
+53.27%
$10.30
AAL
-0.25%
$11.86
NEHC
+44.44%
$4.55
NUAI
+44.44%
$4.55
IONQ
-4.04%
$62.94
WULF
+0.50%
$13.93
NAK
-8.48%
$2.04
NOK
+1.05%
$5.74
ATAI
+17.70%
$6.45
RR
-4.05%
$5.44
SMR
-7.11%
$44.25
CLSK
-2.32%
$19.52
GWH
+16.04%
$5.28
APLD
-6.55%
$34.24
CRWV
-3.43%
$136.87
YGMZ
-6.12%
$0.92
UUUU
-2.90%
$21.06
QS
-0.64%
$15.36
GOOGL
+0.73%
$253.30
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
VALE
-0.09%
$11.10
WLGS
-5.57%
$0.04
FNB
+3.00%
$15.09
BULL
-6.29%
$11.01
AG
-8.48%
$14.03
FEMY
-5.67%
$0.70
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.